Press Release June 14, 2019

Ginkgo Bioworks and Synlogic Collaborate to Accelerate the Development of Novel Synthetic Biotic™ Medicines

The Life Sciences team advised Ginkgo Bioworkson its collaboration with Synlogic, Inc. (Nasdaq: SYBX), to accelerate the expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform. Synlogic will use Ginkgo’s cell programming platform for building and testing thousands of microbial strains to accelerate progression of early preclinical leads to drug candidates optimized for further clinical development.

The agreement provides an $80 million equity investment in Synlogic by Ginkgo and an upfrontpayment of $30 million by Synlogic to Ginkgo for research and development to be provided over an initial period of five years, which can be extended for an additional three years.

Ginkgo Bioworks is the organism company, using the power of biology to build sustainable products in food, pharma, manufacturing, and more. Using sophisticated software and state of the art automation, Ginkgo's powerful platform for genetic engineering is making biology easier to engineer, enabling new products to be renewably manufactured with biology.

The Goodwin team was led by partner Karen Spindler and associate Erin Svokos, and included partners Robert Puopolo and Daniel Karelitz and associate Jonathan LaPlante.

For more details on the collaboration, please read the press release.